Hagop Kantarjian, Deborah Thomas, Susan O'Brien, Jorge Cortes, Francis Giles, Sima Jeha, Carlos E. Bueso-Ramos, Sherry Pierce, Jianqin Shan, Charles Koller, Miloslav Beran, Michael Keating and Emil J. Freireich Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia Cancer 101
Version of Record online: 12 OCT 2004 | DOI: 10.1002/cncr.20668
Modern intensive chemotherapy regimens have improved the prognosis for patients with adult acute lymphocytic leukemia. With these regimens, the complete response rates are now reported to be > 80%, and the long-term survival rates range from 30% to 45%. The current analysis updated the long-term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone program, with a median follow-up time of 63 months.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field